What is the EFSA tolerable upper intake level (UL) for vitamin B6 in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

EFSA Tolerable Upper Intake Level for Vitamin B6 in Adults

The EFSA established a tolerable upper intake level (UL) of 12 mg/day for vitamin B6 in adults, including pregnant and lactating women 1.

Key Details of the UL Determination

The EFSA Panel on Nutrition, Novel Foods and Food Allergens conducted a comprehensive scientific opinion in 2023 specifically addressing vitamin B6 upper limits 1. This represents the most current and authoritative guidance on this topic.

Critical Effect and Rationale

  • Peripheral neuropathy was identified as the critical adverse effect from excess vitamin B6 intake
  • The Panel identified a reference point of 50 mg/day from a case-control study, supported by case reports and vigilance data
  • An uncertainty factor of 4 was applied to account for:
    • The inverse relationship between dose and time to onset of symptoms
    • Limited available data on the precise LOAEL (lowest-observed-adverse-effect-level)
  • This calculation (50 mg ÷ 4) yielded 12.5 mg/day, which was rounded to 12 mg/day 1

Age-Specific ULs

The adult UL was scaled down for younger populations using allometric scaling (body weight^0.75) 1:

  • Infants (4-11 months): 2.2-2.5 mg/day
  • Children (1-6 years): 3.2-4.5 mg/day
  • Children/Adolescents (7-17 years): 6.1-10.7 mg/day
  • Adults (≥18 years): 12 mg/day

Important Clinical Caveats

Lower-Dose Toxicity Concerns

Recent evidence challenges the assumption that only mega-doses cause toxicity. A 2023 case report documented peripheral neuropathy in a patient taking only 6 mg/day from a multivitamin—half the established UL—with elevated serum B6 levels of 259.9 nmol/L 2. This highlights that:

  • Individual susceptibility varies considerably
  • The UL represents a population-level safety threshold, not an absolute guarantee of safety for all individuals
  • Patients developing neurological symptoms should have vitamin B6 intake assessed even at "low" supplemental doses

Comparison to Other Guidelines

The 2022 ESPEN guideline cites older reference values with higher ULs 3:

  • Ages 14-18 years: 80 mg/day
  • Ages 19-70+ years: 100 mg/day

These older values are superseded by the 2023 EFSA assessment, which used more rigorous systematic review methodology and incorporated more recent safety data showing toxicity at lower doses 1.

Population Risk Assessment

Based on available intake data, EU populations are unlikely to exceed the 12 mg/day UL from diet alone. The primary risk group is regular users of food supplements containing high doses of vitamin B6 1.

Practical Recommendations

  • Review all sources of vitamin B6 in patients taking supplements (multivitamins, B-complex, individual B6 supplements)
  • For patients developing peripheral neuropathy, obtain detailed supplement history and consider serum B6 measurement
  • The washout period for complete vitamin B6 clearance is 20-40 days based on pharmacokinetic parameters 4
  • Advise against routine supplementation above the recommended dietary allowance (1.3-1.7 mg/day for adults) unless clinically indicated 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.